Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc.
- Market cap
- $40.51M
Your view on ALDX
Overview
What the company does, where it operates, and who runs it.
About Aldeyra Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Todd C. Brady
- Headquarters
- 131 Hartwell Avenue, Lexington, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Todd C. Brady
- Headquarters
- 131 Hartwell Avenue, Lexington, MA, US
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis.
It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma.
The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.
Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Aldeyra Therapeutics, Inc.. Starting points for Aldeyra Therapeutics, Inc.: EPS -$0.32, beta 1.29 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Aldeyra Therapeutics, Inc.. Trailing twelve-month EPS for Aldeyra Therapeutics, Inc. stands at -$0.32. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
19 ratings- Strong Buy0
- Buy18
- Hold1
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.08 | −$0.06 | −$0.30 | −$0.25 |
| Lowest estimate | −$0.08 | −$0.06 | −$0.39 | −$0.33 |
| Highest estimate | −$0.08 | −$0.06 | −$0.20 | −$0.17 |
| Number of analysts | 2 | 1 | 2 | 3 |
| A year ago | −$0.11 | −$0.06 | −$0.56 | — |
| Growth vs a year ago | +30.9% | +0.0% | +47.1% | — |
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $0.00 | $0.00 | $1.25M | $9.48M |
| Lowest estimate | $0.00 | $0.00 | $951870.00 | $7.22M |
| Highest estimate | $0.00 | $0.00 | $1.55M | $11.74M |
| Number of analysts | 0 | 0 | 2 | 3 |
| A year ago | $0.00 | $0.00 | $0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Aldeyra Therapeutics, Inc.. Aldeyra Therapeutics, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ACIUAC Immune S.A. | Healthcare | Biotechnology | $213.7M | ||
| AMRNAmarin Corporation plc | Healthcare | Drug Manufacturers - General | $232.9M | ||
| ANROAlto Neuroscience, Inc. | Healthcare | Biotechnology | $1.0B | ||
| CADLCandel Therapeutics, Inc. | Healthcare | Biotechnology | $417.3M | ||
| CLLSCellectis S.A. | Healthcare | Biotechnology | $103.8M | ||
| CTNMContineum Therapeutics, Inc. Class A Common Stock | Healthcare | Biotechnology | $326.7M | ||
| GNLXGenelux Corporation | Healthcare | Biotechnology | $107.7M | ||
| KYTXKyverna Therapeutics, Inc. | Healthcare | Biotechnology | $283.2M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PXMDPaxMedica, Inc. Common Stock | Healthcare | OTC | $37,879 | ||
| PXXLFPoxel S.A. | Healthcare | OTC | $13.4M | ||
| PYC.AXPYC Therapeutics Limited | Healthcare | ASX | — | ||
| OBXObsidian Therapeutics Inc. | Healthcare | NASDAQ | $12.7M | ||
| OCC.AXOrthocell Limited | Healthcare | ASX | — | ||
| OCEAOcean Biomedical, Inc. | Healthcare | PNK | $1.2M | ||
| OCGNOcugen, Inc. | Healthcare | NASDAQ | $250.8M | ||
| OCSOculis Holding AG | Healthcare | NASDAQ | $456.2M | ||
| OCULOcular Therapeutix, Inc. | Healthcare | NASDAQ | $1.3B | ||
| ODTXOdyssey Therapeutics, Inc. | Healthcare | NASDAQ | $912.3M | ||
| OGENOragenics, Inc. | Healthcare | AMEX | $852,760 | ||
| OKUROnKure Therapeutics, Inc. | Healthcare | NASDAQ | $114.2M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.00% | |
| IWCiShares Micro-Cap ETF | $1.2B in assets | 0.01% | |
| VHTVanguard Health Care ETF | $19.1B in assets | 0.00% | |
| PRFZInvesco RAFI US 1500 Small-Mid ETF | $2.6B in assets | 0.00% | |
| QQQSInvesco NASDAQ Future Gen 200 ETF | $20M in assets | 0.31% | |
Largest holders first, then the funds most concentrated in ALDX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Aldeyra Therapeutics, Inc., and how their positions are changing. At a $40.5M market value, institutional positions materially move Aldeyra Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Aldeyra Therapeutics, Inc. executives and directors. Shares of Aldeyra Therapeutics, Inc. have traded between $1.14 and $7.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Aldeyra Therapeutics, Inc.. Coverage tracks Aldeyra Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Aldeyra Therapeutics, Inc.